The first missense mutation causing Rett syndrome specifically affecting the MeCP2_e1 isoform
- 196 Downloads
We report the identification of the first de novo mutation at a highly conserved residue within the polyalanine stretch in the N-terminal region of the brain-dominant protein isoform MeCP2_e1 in a girl with classical Rett syndrome. The missense mutation, p.Ala2Val, leads to severe developmental delay, microcephaly, no language, severe epilepsy, and cognitive impairment. To evaluate the pathogenic potentials of the MECP2 mutation specific to the MeCP2_e1 isoform detected in this patient, full-length wild-type and mutated cDNAs were cloned in eukaryotic expression vectors to generate a fusion protein with c-myc, and constructs were transfected in COS7 cells. In vitro studies demonstrated that, like wild-type MeCP2e_1, the N-terminal mutant is localized in the nucleus. Neither transcriptional nor translational effect on the MeCP2_e2 isoform was observed in fibroblasts from the p.Ala2Val patient, suggesting that MeCP2_e1 is involved in other functional process. These data suggest the important involvement of the N-terminus in the function of MeCP2 protein, and provide further evidence for the major impact of a specific MeCP2e_1 deficiency in the development of intellectual processing.
KeywordsMECP2 Rett syndrome Isoforms Missense mutation
This work was supported by a grant of ANR-Maladies rares (ANR-6-MRAR-003-01; ANR-e-Rare EuroRETT). JN is currently funded by INSERM (Institut National la Recherche Scientifique; Poste d’acceuil).
- 3.Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, MacLeod PJ, Jones JR, Scherer SW, Schanen NC, Friez MJ, Vincent JB, Minassian BA (2004) A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat Genet 36:339–341. doi: 10.1038/ng1327 CrossRefPubMedGoogle Scholar
- 5.Bartholdi D, Klein A, Weissert M, Koenig N, Baumer A, Boltshauser E, Schinzel A, Berger W, Mátyás G (2006) Clinical profiles of four patients with Rett syndrome carrying a novel exon 1 mutation or genomic rearrangement in the MECP2 gene. Clin Genet 69:319–326. doi: 10.1111/j.1399-0004.2006.00604.x CrossRefPubMedGoogle Scholar
- 10.Hagberg B, Hanefeld F, Percy A, Skjeldal O (2002) An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden, Germany, 11 September 2001. Eur J Paediatr Neurol 6:293–297. doi: 10.1053/ejpn.2002.0612 CrossRefPubMedGoogle Scholar
- 11.Kerr AM, Nomura Y, Armstrong D, Anvret M, Belichenko PV, Budden S, Cass H, Christodoulou J, Clarke A, Ellaway C, d’Esposito M, Francke U, Hulten M, Julu P, Leonard H, Naidu S, Schanen C, Webb T, Engerstrom IW, Yamashita Y, Segawa M (2001) Guidelines for reporting clinical features in cases with MECP2 mutations. Brain Dev 23:208–211. doi: 10.1016/S0387-7604(01)00193-0 CrossRefPubMedGoogle Scholar
- 18.Kumar A, Kamboj S, Malone BM, Kudo S, Twiss JL, Czymmek KJ, LaSalle JM, Schanen NC (2008) Analysis of protein domains and Rett syndrome mutations indicate that multiple regions influence chromatin-binding dynamics of the chromatin-associated protein MECP2 in vivo. J Cell Sci 121:1128–1137 . doi: 10.1242/jcs.016865 CrossRefPubMedGoogle Scholar